Satellite Meeting – EuroMedLab 2015
HbA1c and management of diabetes mellitus
in the 21st Century
Friday, June 26th, 2015
Reims, France
Organized under the auspices of SFBC, SFD*, EFLM*, IFCC*
(*in progress)
*******
International Scientific Committee :
Dr Michèle Fonfrède, Prof. Philippe Gillery, Prof. Garry John,
Prof. Andrea Mosca, Prof. Bernard Vialettes, Dr Cas Weykamp
Local Organizing Committee :
Dr Aurore Desmons, Prof. Philippe Gillery, Dr Emmanuelle Guillard,
Dr Stéphane Jaisson, Dr Nathalie Schneider
Diabetes mellitus is an increasing global problem for public health which requires the availability of reliable biomarkers for the optimal patient care. Haemoglobin A1c (HbA1c) has proved itself to be vital for the management of patients with diabetes and improvements in methods has enabled global targets to be set for treatment and diagnosis.
This symposium will present the most recent advances in the management of diabetes mellitus focussing on HbA1c and new biomarkers. Additionally, new aspects of HbA1c analysis (e.g. in diabetes diagnosis or point of care testing) will be debated according to both clinical and biological points of views.
International experts in the field of diabetes and laboratory medicine, especially those involved in the IFCC reference network on HbA1c, will give presentations and participate in debates.
This meeting is intended for clinical chemists and diabetologists, who will hear the most recent information for use in their daily practice and new perspectives for the future.
Chairman /
speaker
0930 – 0945 : Welcome addresses
0945 – 1105 : Session 1 : Diabetes mellitus and HbA1c : Michel Marre (FR)
global challenges
0945 – 1025 : Diabetes Mellitus : Andre Scheen (BE)
The Challenge for the 21st century
1025 – 1105 : HbA1c: History, Science and Politics Garry John (UK)
1105 – 1130 : Tea/Coffee break
1130 – 1315 : Session 2 : Is HbA1c fit for its clinical purpose ? Andrea Mosca (IT)
1130 – 1210 : A standardised HbA1c is vital for clinical practice Cas Weykamp (NL)
1210 – 1315 : Debate : The diagnosis of diabetes mellitus : David Sacks (US)
a movable feast (pro and con) Eric Kilpatrick (UK)
1315 – 1430 : Lunch
1430 – 1600 : Session 3 : Debate : Using HbA1c in clinical practice : Bernard Vialettes (FR)
what do I need to know ?
1430 – 1500 : Renal Failure! Can I use HbA1c? Michel Marre (FR)
1500 – 1530 : HbA1c analysis in the presence of Hb variants Randie Little (US)
1530 – 1600 : HbA1c : is POCT good enough? Sverre Sandberg (NO)
1600 – 1630 : Tea/coffee break
1630 – 1730 : Session 4 : Perspective in diabetes biomarkers Philippe Gillery (FR)
1630 – 1650 : HbA1c beyond diabetes! Emma English (UK)
1650 – 1710 : Glycated albumin: time for a resurgence Andrea Mosca (IT)
1710 – 1730 : Future markers in diabetes monitoring Michèle Fonfrède (FR)
(1,5-anhydroglucitol, AGEs, non invasive technologies)
1730 : Conclusions and end of the meeting
|